Please provide your email address to receive an email when new articles are posted on . EASI 75 and validated IGA-AD 0/1 response rates from week 16 were maintained through week 140. No new safety ...
To launch its new rheumatoid arthritis pill Rinvoq into an already crowded therapy area, AbbVie is leading with a DTC campaign meant to empower patients to “take on” the disease. A newly debuted TV ad ...
Zacks Investment Research on MSN
How AbbVie's pipeline is lining up key product launches
AbbVie ABBV has been consistently increasing its R&D investments to support long-term growth across multiple therapeutic ...
AbbVie ABBV announced positive results from its mid-stage study evaluating Rinvoq (upadacitinib) in a new indication. The phase IIb study evaluated the 6 mg, 11 mg and 22 mg dose strengths of Rinvoq ...
In December 2021, the US Food and Drug Administration (FDA) approved upadacitinib (Rinvoq ® [AbbVie, Inc.]), a Janus kinase (JAK) inhibitor, for the treatment of adults with active psoriatic arthritis ...
Rinvoq is the first oral drug for moderate to severe Crohn’s disease — a chronic intestinal disorder — to be approved by the Food and Drug Administration. There is no cure for Crohn’s disease, and the ...
"There remains an unmet need for patients with moderately to severely active UC, who suffer from debilitating symptoms that are often unpredictable and burdensome," said Thomas Hudson, MD, senior vice ...
NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety ...
RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback